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Measuring Impact
of Antimicrobial
Resistance
To the Editor: Staphylococcus
aureus and  Enterococcus faecium
commonly cause healthcare-associat-
ed bloodstream infections (BSI) in the
intensive care unit (ICU). Antimicro-
bial resistance is increasing in both
organisms. The impact of antimicro-
bial resistance on dying of BSI has
been studied extensively (1,2). Many
studies have concluded that BSI
caused by an antimicrobial-resistant
organism results in higher death rates
(1,3–8). However, as discussed in a
recent report by Kaye et al., “outcome
studies of antimicrobial drug resist-
ance are notoriously hard to perform
because of confounding variables
related to coexisting conditions” (9).
Indeed, almost all studies have shown
that infections with antimicrobial-
resistant organisms occur later in hos-
pitalization than infections with
antimicrobial-susceptible organisms,
which suggests that differences in
death rates may be, at least in part,
caused by a difference in the patients’
underlying illnesses and protracted
hospital course. We report 2 addition-
al methodologic issues that can affect
estimates of the impact of antimicro-
bial resistance: combining different
organisms and combining populations
from different types of ICUs. 
The original objective of our mul-
ticenter observational study was to
quantify the clinical impact of antimi-
crobial resistance in S. aureus and E.
faecium infections when these bacte-
ria cause a specific type of infection: a
monomicrobial, ICU-attributable,
central vascular catheter–associated
bloodstream infection (CVC-BSI).
We studied 187 adult ICU patients
with BSI caused by S. aureus and E.
faecium at 3 tertiary care institutions
from 1994 to 1999. The institutional
review boards of each institution and
the Centers for Disease Control and
Prevention approved this study.
Severity of illness was measured with
an APACHE II score at ICU admis-
sion and on day 7 in the ICU (if appli-
cable). The score would indicate the
patient’s risk of dying in the hospital
before a BSI developed by using a
measure validated for predicting in-
hospital deaths in ICU patients (10).
The study population stratified by
organism is shown in the Table. Fifty-
eight percent of patients had CVC-
BSI with S. aureus, and 42% had
CVC-BSI with E. faecium. Overall,
58% of the organisms causing CVC-
BSI were resistant to oxacillin if S.
aureus or to vancomycin if E. faeci-
um. However, patients with E. faeci-
um CVC-BSI were more likely to be
infected with antimicrobial-resistant
bacteria (69% versus 50%, p<0.01),
and had a higher mortality rate (54%
versus 34%, p<0.01) than patients
with S. aureus CVC-BSI. This finding
indicates that the type of organism (E.
faecium versus S. aureus) confounds
the association between resistance
and death. In addition, the distribution
of ICU type by organism varies,
which suggests that patient popula-
tions infected with these 2 different
organisms were different in other
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ways. Thus, confounding factors for
the association between resistance
and death may differ for E. faecium
and S. aureus, and analysis of the 2
organisms should be conducted sepa-
rately. This is consistent with the
results of Kaye et al. who showed that
the effect of resistance was higher for
S. aureus (odds ratio [OR] 3.4) than
for E. faecium (OR 2.5) by using sep-
arate analyses to show death rates (9).
Furthermore, these researchers found
different confounding factors in the
adjusted analysis of S. aureus than in
the adjusted analysis of E. faecium.
Because of the need to conduct sepa-
rate analyses, which reduced our sta-
tistical power, our study was ultimate-
ly unable to show a difference in
death rates if it existed. 
In summary, future studies meas-
uring the impact of antimicrobial
resistance on death rates should be
restricted to a specific type of infec-
tion cause by a single organism in a
uniform setting using a validated sys-
tem to predict mortality in that setting.
As such, future studies should involve
multiple study sites.
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Antimicrobial
Resistance in
Campylobacter
To the Editor: Iovine and Blaser
(1) write, “This therapeutic use [of
enrofloxacin] was withdrawn (2) but
is now under appeal” and “Despite the
restrictions on enrofloxacin use,
emergence of fluoroquinolone-resist-
ant  Campylobacter  species, with
poultry as an important source, has
been documented in the United
States… Therefore, our conclusion
remains: use of enrofloxacin in poul-
try materially contributed to increase
in human infection by fluoro-
quinolone-resistant  Campylobacter
species.”
These claims propagate the fol-
lowing important errors. First, the
therapeutic use of enrofloxacin was
not withdrawn. Judge Davidson’s
order to withdraw the approval was an
initial decision, to which exceptions
were filed in 2004. A final decision
rests with the US Food and Drug
Administration Commissioner.
Second, poultry has not been iden-
tified as an important source of fluo-
roquinolone resistance in human
Campylobacter isolates. The raw data
of the cited Smith et al. article (3)
indicate a nonsignificant negative
association between chicken con-
sumption and fluoroquinolone resist-
ance in human isolates. Substantial
resistance levels in Northern
Hemisphere countries with and with-
out enrofloxacin use, which occurred
well before fluoroquinolones were
ever used in animals (3–5), also sug-
gest that attribution of such resistance
to enrofloxacin is simplistic. 
Finally, rational decision-making is
based on probable future consequences
of a decision, not past history or caus-
es of the current situation. Iovine and
Blaser’s claim, “Thus the decision to
withdraw therapeutic use of
enrofloxacin (3) was warranted,” is not
implied, even if enrofloxacin use
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